0001209191-23-053269.txt : 20231020 0001209191-23-053269.hdr.sgml : 20231020 20231020164048 ACCESSION NUMBER: 0001209191-23-053269 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231019 FILED AS OF DATE: 20231020 DATE AS OF CHANGE: 20231020 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jenkins Abigail L. CENTRAL INDEX KEY: 0001947032 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38716 FILM NUMBER: 231337516 MAIL ADDRESS: STREET 1: C/O GAMIDA CELL LTD. STREET 2: 116 HUNTINGTON AVENUE CITY: BOSTON STATE: MA ZIP: 02116 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Gamida Cell Ltd. CENTRAL INDEX KEY: 0001600847 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 NAHUM HAFZADI STREET CITY: JERUSALEM STATE: L3 ZIP: 95484 BUSINESS PHONE: 97226595666 MAIL ADDRESS: STREET 1: 5 NAHUM HAFZADI STREET CITY: JERUSALEM STATE: L3 ZIP: 95484 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-19 0 0001600847 Gamida Cell Ltd. GMDA 0001947032 Jenkins Abigail L. C/O GAMIDA CELL LTD. 116 HUNTINGTON AVENUE BOSTON MA 02116 1 1 0 0 President and CEO 0 Ordinary Shares 2023-10-19 4 A 0 109013 0.00 A 375142 D Employee Share Option (Right to Buy) 1.59 2023-10-19 4 A 0 217954 0.00 A 2033-10-18 Ordinary Shares 217954 217954 D The restricted stock unit ("RSU") award was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the award at the annual general meeting of the shareholders on October 19, 2023. Represents an RSU award, which vested or shall vest with respect to 33% of the RSUs, on each of August 8, 2023 and August 8, 2024, respectively, and with respect to 34% of the RSUs, on August 8, 2025. The vesting of the RSUs is subject to the Reporting Person's continuous service through each such vesting date. The option grant was approved by the Board of Directors of the Issuer on February 8, 2023, subject to shareholder approval. The Issuer's shareholders approved the grant at the annual general meeting of the shareholders on October 19, 2023. 33% of the shares subject to the option award vested or shall vest on each of August 8, 2023 and August 8, 2024, respectively, and 34% of the shares subject to the option award shall vest on August 8, 2025, subject to the Reporting Person's continuous service through such vesting date. /s/ Joshua F. Patterson, Attorney-in-Fact 2023-10-20